Open access peer-reviewed Edited Volume


Ahmed Lasfar

Rutgers University


Karine Cohen-Solal

Rutgers University


Metastatic Melanoma Skin Cancer BRAF Mutation BRAF Inhibitor RAS mutation NF1 Mutation MEK Inhibitor Immune Checkpoint Inhibitor PD-1 CTL-A4 Adjuvant Therapy Melanoma

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

With an incidence increasing over the past 30 years, cutaneous melanoma, representing about 1% of skin cancers, is causing the majority of skin cancer-related death. With four major genomic subtypes, BRAF-mutated, RAS-mutated, NF1-mutated and the triple wild-type subtype, targeted therapies only demonstrated efficacy and received approval for the BRAF-mutant melanoma subtype. Although combination therapies with dual BRAF/MEK inhibition have shown improvement in clinical outcomes over a single-agent inhibitor alone, a large majority of patients eventually acquire resistance to therapy and relapse, through numerous mechanisms. Immune checkpoint inhibitors (ICIs), acting through CTLA-4 targeting and PD1 blockade, are now part of both first- and subsequent-line treatment options, and their use has resulted in dramatic improvements in outcomes, shifting survival from months to years for some melanoma patients.

Furthermore, the approval of these ICIs in the adjuvant setting for resectable melanoma represents further major advances for patients with locally advanced disease and involvement of regional lymph nodes; ICIs are effective regardless of BRAF status, placing ICIs as equally weighted first-line therapy options, along with targeted therapy, for patients with BRAFV600 mutation.

In this book, we will provide recent breakthroughs in melanoma development and metastasis, and discuss current treatment modalities and ongoing clinical trials.

Publishing process

Book initiated and editor appointed

Date completed: May 8th 2020

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline for chapter proposals: May 29th 2020

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Register for the book

Approved chapters written in full and submitted

Deadline for full chapters: July 28th 2020

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: October 16th 2020

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: December 15th 2020

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Ahmed Lasfar

Rutgers University

Dr. Ahmed Lasfar is a member of the Cancer Institute of New Jersey, Principal Investigator and a faculty member at Ernest Mario School of Pharmacy, Rutgers University, New Jersey. Dr. Lasfar laboratory focuses on Interferon, Cancer and Immunology. Dr. Lasfar serves as Editor of several international journals and books. He is a Board member and Reviewer of many journals and foundations. He also serves as a Scientific Adviser for pharmaceutical industry. Dr. Lasfar graduated in France from Paris Rene Descartes University on medical and applied science. He completed his doctoral studies in Immunology at Paris Diderot University in a joint program with Pasteur Institute and his postdoctoral training in cancer immunology with Dr. Sidney Pestka at Robert Wood Johnson Medical School, New Jersey.

View profile

Book chapters authored 2

Books edited 2

Introducing your Author Service Manager

Ms. Ivana Barac

As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact.

Ask a question

Book will be abstracted and indexed in